Indolent Systemic Mastocytosis — Trials

Indolent Systemic Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05186753	(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis	active not recruiting	Phase 2	237	Cogent Biosciences, Inc.INDUSTRY	15	May 22, 2026	clinicaltrials
NCT03731260	(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis	active not recruiting	Phase 2	251	Blueprint Medicines CorporationINDUSTRY	13	Sep 23, 2025	clinicaltrials

Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials